Intensity Therapeutics Files 8-K on Officer Changes and Shareholder Votes
Ticker: INTS · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, shareholder-vote
TL;DR
Intensity Therapeutics 8-K: Leadership changes and shareholder votes filed July 17, 2024.
AI Summary
Intensity Therapeutics, Inc. filed an 8-K on July 17, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, and submission of matters to a vote of security holders. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially if numerous or unexpected, can signal internal challenges or strategic realignments that may affect the company's future performance.
Key Players & Entities
- INTENSITY THERAPEUTICS, INC. (company) — Registrant
- July 17, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-41109 (company_id) — SEC File Number
- 46-1488089 (tax_id) — IRS Employer Identification No.
- 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 (address) — Principal Executive Offices
- 203-221-7381 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in this summary section of the 8-K.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
Are there any new compensatory arrangements for officers mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, suggesting such arrangements are part of the report, but specific details are not included here.
What financial statements or exhibits are included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content of these is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 17, 2024.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-07-17 16:01:57
Key Financial Figures
- $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
Filing Documents
- intensity-20240717.htm (8-K) — 38KB
- 0001567264-24-000035.txt ( ) — 168KB
- intensity-20240717.xsd (EX-101.SCH) — 2KB
- intensity-20240717_lab.xml (EX-101.LAB) — 23KB
- intensity-20240717_pre.xml (EX-101.PRE) — 13KB
- intensity-20240717_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. At the Annual Meeting, 8,522,632 shares of common stock, or approximately 62.15% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum. At the Annual Meeting, the stockholders of the Company voted as set forth below on three proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 4, 2024. The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Election of Directors. The election of two Class I directors, each to hold office until the 2027 annual meeting of stockholders or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Daniel Donovan 6,676,800 58,854 1,786,978 Thomas I. H. Dubin 6,732,229 3,425 1,786,978 Proposal 2. Approval of the ESPP. The approval of the ESPP. For Against Abstain Broker Non-Votes 6,624,163 103,613 7,878 1,786,978 Proposal 3. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the Board of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. For Against Abstain 8,516,892 4,017 1,723
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Intensity Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on June 4, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 17, 2024 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer 2